What is the appropriate hormonal therapy regimen for prostate cancer?

Hormonal Therapy in Prostate Cancer

For metastatic castration-sensitive prostate cancer, androgen deprivation therapy (ADT) combined with intensification using docetaxel, abiraterone, enzalutamide, or apalutamide represents the standard of care, with each combination showing superior outcomes compared to ADT alone. 1

Risk-Stratified Approach to Hormonal Therapy

Low-Risk Localized Disease

• Hormonal therapy is NOT recommended as primary treatment 2, 3
• Active surveillance or watchful waiting with delayed hormone therapy are appropriate options 2, 3
• No benefit for active treatment has been demonstrated in overall survival 3

Intermediate-Risk Localized Disease

• Neoadjuvant ADT for 4-6 months should be considered for men receiving radical radiotherapy 3, 2
• External beam RT plus ADT or radical prostatectomy are treatment options 3
• The neoadjuvant hormonal therapy improves outcomes when combined with RT 2

High-Risk or Locally Advanced Disease

• External beam RT plus hormone treatment for at least 2 years is strongly recommended 3
• Neoadjuvant LHRH agonist therapy for 4-6 months is recommended for men receiving radical RT 3, 2
• Adjuvant ADT for 2-3 years is recommended for men receiving neoadjuvant hormonal therapy and radical RT who are at high risk of prostate cancer mortality 3, 2
• This combination improved 5-year overall mortality from 19.0% to 15.2% in the EORTC 22961 trial 2

Metastatic Castration-Sensitive Disease

First-Line Treatment

• Chemical or surgical castration should be the foundation of first-line hormonal management 3
• Treatment intensification with ADT plus docetaxel, abiraterone, enzalutamide, or apalutamide represents four separate standards of care 1, 4
• Combined androgen blockade (castration plus anti-androgen) confers minimal survival benefit with increased toxicity and cost, and is NOT routinely recommended 3, 5
• Short-course anti-androgen should be used to prevent disease flare when starting an LHRH agonist 6, 7, 3

Specific Agents

• LHRH agonists (e.g., leuprolide) or LHRH antagonists achieve equivalent testosterone reduction 3
• Bilateral orchiectomy remains an effective alternative with equivalent efficacy to medical castration 8, 5

Biochemical Recurrence After Radical Therapy

• Hormonal therapy is NOT routinely recommended for biochemical relapse alone 3
• Hormonal therapy should be reserved for: symptomatic local disease progression, proven metastases, or PSA doubling time <3 months 3, 6
• Intermittent ADT is not inferior to continuous ADT and has quality-of-life benefits 3
• Intermittent ADT may be offered to men with high-risk biochemically recurrent nonmetastatic prostate cancer 1

Castration-Resistant Prostate Cancer (CRPC)

Hormonal Management

• Patients should continue androgen suppression despite castration resistance 3
• Second-line hormone therapies should be considered: anti-androgens, corticosteroids, abiraterone, or enzalutamide 3
• In patients progressing following docetaxel, treatment with abiraterone or enzalutamide should be discussed if not used previously 3
• Abiraterone pre-docetaxel improved radiographic progression-free survival (16.5 vs 8.3 months) 3

Chemotherapy Integration

• Docetaxel using a 3-weekly schedule should be considered for symptomatic, castration-resistant disease 3, 6, 7
• Median survival was 19.2 months with 3-weekly docetaxel versus 16.3 months with mitoxantrone 3
• Chemotherapy might be preferable in those with poor initial hormone response or severe symptoms 3

Critical Timing Considerations

Early vs. Deferred ADT

• For metastatic disease at presentation, immediate ADT may be offered to men with locally advanced nonmetastatic disease who have not undergone previous local treatment and are unwilling or unable to undergo radiotherapy 1
• Early treatment with LHRH agonists confers a small but statistically significant survival advantage in metastatic disease 5
• Until modern diagnostic data become available, no specific recommendation can be made regarding early versus deferred ADT timing for asymptomatic patients 5

Common Pitfalls to Avoid

• Do not use adjuvant hormone therapy after radical prostatectomy alone—it is not recommended 3
• Do not use pure anti-androgens as monotherapy for localized disease—they are associated with poorer outcomes compared to watchful waiting 8, 5
• Do not discontinue androgen suppression when disease becomes castration-resistant—continue ADT while adding additional therapies 3
• Do not routinely use combined androgen blockade as first-line therapy—the minimal survival benefit does not justify the increased cost and toxicity 3